Core Insights - Edgewise Therapeutics, Inc. is participating in the 30th International Annual Congress of the World Muscle Society (WMS) to present long-term data on sevasemten, demonstrating sustained disease stabilization in Becker muscular dystrophy compared to natural history [1][2]. Company Overview - Edgewise Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions, with a strong emphasis on muscle physiology [7]. - The company is advancing sevasemten, a first-in-class fast skeletal myosin inhibitor, currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies [7]. Product Information - Sevasemten is designed to prevent contraction-induced muscle damage in muscular dystrophies, with a unique mechanism of action that limits muscle damage due to the absence of functional dystrophin [5]. - The product has received several regulatory designations, including FDA Orphan Drug Designation and Fast Track designations for Becker and Duchenne muscular dystrophies, as well as EMA Orphan Drug Designations [5]. Upcoming Events - The Edgewise symposium at WMS will take place on October 8, 2025, featuring key opinion leaders discussing the clinical progress of sevasemten and results from the CANYON and MESA trials [2]. - Scientific posters detailing trial results will be presented on October 10, 2025, highlighting the efficacy of sevasemten in reducing muscle damage biomarkers and stabilizing function in Becker muscular dystrophy [3].